ALK – Finanskalender for regnskabsåret 2025
20 déc. 2024 11h09 HE
|
ALK Abello
Finanskalender 2025 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22. januar 2025: Stilleperiode19. februar 2025: Offentliggørelse af årsrapport 202413. marts 2025 kl. 16.00:...
ALK – Financial calendar for the 2025 financial year
20 déc. 2024 11h09 HE
|
ALK Abello
2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report...
Positive resultater fører peanut-tablet videre til fase II-udvikling
18 déc. 2024 06h51 HE
|
ALK Abello
ALKs peanut-tablet påvist at være sikker og veltolereret på tværs af flere forskellige doserUdviklingen går nu ind i fase II, hvor dosisvalg og effekt undersøgesDe første patienter i fase II vil snart...
Positive results advance peanut tablet to phase II development
18 déc. 2024 06h51 HE
|
ALK Abello
ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses...
ACARIZAX® godkendt i Europa til behandling af yngre børn
12 déc. 2024 10h06 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn i alderen fem til 11 år er blevet...
ACARIZAX® approved in Europe for treatment of young children
12 déc. 2024 10h06 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been...
ALK’s pivotal phase 3 trial in children published in reputable scientific journal
27 nov. 2024 07h45 HE
|
ALK Abello
The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children...
Nine-month interim report (Q3) 2024 (unaudited) - English version only
14 nov. 2024 01h30 HE
|
ALK Abello
Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales...
Nine-month interim report (Q3) 2024 (unaudited)
14 nov. 2024 01h30 HE
|
ALK Abello
Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet...
ALK indlicenserer rettigheder til neffy®, den første godkendte næsespray med adrenalin til akut behandling af allergiske reaktioner (anafylaksi)
09 nov. 2024 17h30 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabet har indgået en strategisk licensaftale med USA-baserede ARS Pharmaceuticals, Inc. (”ARS Pharma”) (NASDAQ: SPRY). Aftalen giver ALK...